Biohaven Pharmaceutical Holding Debt to Equity Ratio 2016-2022 | BHVN
Current and historical debt to equity ratio values for Biohaven Pharmaceutical Holding (BHVN) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Biohaven Pharmaceutical Holding debt/equity for the three months ending March 31, 2022 was 0.00.
| Biohaven Pharmaceutical Holding Debt/Equity Ratio Historical Data |
| Date |
Long Term Debt |
Shareholder's Equity |
Debt to Equity Ratio |
| 2022-03-31 |
$1.84B |
$-0.47B |
-3.94 |
| 2021-12-31 |
$1.82B |
$-0.74B |
-2.45 |
| 2021-09-30 |
$1.72B |
$-0.59B |
-2.91 |
| 2021-06-30 |
$1.30B |
$-0.46B |
-2.85 |
| 2021-03-31 |
$1.28B |
$-0.28B |
-4.61 |
| 2020-12-31 |
$1.08B |
$-0.39B |
-2.75 |
| 2020-09-30 |
$1.00B |
$-0.21B |
-4.66 |
| 2020-06-30 |
$0.46B |
$-0.04B |
-12.96 |
| 2020-03-31 |
$0.41B |
$0.12B |
3.37 |
| 2019-12-31 |
$0.35B |
|
0.00 |
| 2019-09-30 |
$0.32B |
$0.12B |
2.69 |
| 2019-06-30 |
$0.30B |
$0.19B |
1.63 |
| 2019-03-31 |
$0.15B |
$0.10B |
1.53 |
| 2018-12-31 |
$0.14B |
$0.15B |
0.92 |
| 2018-09-30 |
$0.13B |
$0.07B |
1.96 |
| 2018-06-30 |
$0.12B |
$0.12B |
1.01 |
| 2018-03-31 |
$0.02B |
$0.11B |
0.17 |
| 2017-12-31 |
$0.02B |
$0.13B |
0.11 |
| 2017-09-30 |
$0.03B |
$0.16B |
0.18 |
| 2017-06-30 |
$0.02B |
$0.19B |
0.11 |
| 2017-03-31 |
$0.04B |
$0.02B |
1.96 |
| 2016-12-31 |
$0.03B |
$-0.00B |
-16.32 |
| 2016-09-30 |
$0.00B |
$0.00B |
0.00 |
| 2016-06-30 |
$0.00B |
$0.00B |
0.00 |
| 2016-03-31 |
$0.00B |
|
0.00 |
| 2015-12-31 |
$0.00B |
$0.00B |
0.74 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$10.248B |
$0.463B |
|
Biohaven Pharmaceutical is a commercial-stage biotechnology company focused on developing, and commercializing products, primarily in the fields of central nervous system diseases, including neurological and rare disorders.
|
